Science Business Insider - "One of the most significant science breakthroughs of 2013"

World Economic Forum - "Microbiome one of Top 10 Emerging Technologies in 2014"

Targetting:

* Obesity

* Cholesterol

* Diabetes

* ...Many more to come.


Key points:

* Food additives not drugs - less regulation thus much quicker and cheaper route to market.

* Shares in issue 72 million - only 45% free float.

* Already talking to DuPont, Kraft Foods, GSK etc.

* Multiple product, Multiple partner opportunities.

* £3m cash - enough for 2+ years.

* 4D Pharma in same field valued at £180m (opti valued at £9m)

Profit taking.

Classic pullback after a near 50% rise.

Helps to make the chart stronger.

OPTI is right at the heart of this...

"This could be the most important scientific breakthrough in our lifetimes..."

http://moneyweek.com/microbiome-important-scientific-breakthrough/

Highest volume ever today (apart from the initial RTO spike).

Another good RNS today.

It's also very encouraging that the major corporations like GlaxoSmithKline, Procter & Gamble, and Tate & Lyle have been doing their own research into microbiome. This confirms that there is huge commercial interest in this new field of science.

And now OPTI have a direct link with that research.

All very positive OPTI.

"We tipped shares in Optiobiotix (LSE:OPTI) just a few months ago at a 9p offer. Knock me down with a feather they closed Friday at 20.75p-21.25p. But the fun is not over yet. We urged you strongly a week ago to buy at up to our limit buy price of 15p as the last chance to get in cheap. We hope that advice was taken even if you ignored the original tip.

Our stated target price is 30p but following a chat on Friday with a well-connected individual we reckon that the shares could head higher than that on short order. For one of the things about Optibiotix is that the share register is pretty tight. Unlike many penny stocks it has not issued shares like confetti and has no need to issue shares.

So what are we expecting in the next few weeks? We hope for further strengthening of the board. We hope for more news out of Nizo, the Dutch firm testing Optibiotix products in yoghurt and… well here’s the big daddy…

We know that the company is talking to really big name multi nationals about deals which would in scale be massive relative to the current market capitalisation as you can see illustrated HERE. Let’s see how rapidly those talks progress. This is certainly not one to be selling. Its fireworks by Christmas on this share tip."

http://www.shareprophets.com/views/9111/optiobiotix-a-share-tip-that-is-flying-gain-to-date-120-more-to-come

Interesting new NED appointment Today...


OptiBiotix Health plc (AIM: OPTI), a Life Sciences business developing compounds to tackle obesity, high cholesterol and diabetes, announces the appointment of Dr Gareth Barker as a Non-Executive Director of the Company.

Dr Gareth Barker is Vice President of Human Nutrition and Health for DSM Nutritional Products Europe AG, the global science-based nutrition company, within Europe, Africa and the Middle East. Prior to this he has worked in a number of roles for DSM including Global Head of Marketing for DSM's Human Nutrition and Health Division and Sales Director in the Asia Pacific region, with responsibilities including launch strategies for Nutraceuticals. Gareth's career has given him extensive experience and understanding of global markets within the health and nutrition sector.

OptiBiotix Health plc

("OptiBiotix" or the "Company")



OptiBiotix showcases weight management product at Health Ingredients Europe



OptiBiotix Health plc(AIM: OPTI), the Life Sciences business developing compounds to tackle obesity, high cholesterol and diabetes, announces that its weight management yoghurt will be showcased at the Health Ingredients Europe conference in Amsterdam from December 2nd - 4th 2014. The product will be available on the Nizo Food Research stand and will be supported by product samples. The stand number is J2.



Health Ingredients Europe (HiE) is the largest European exhibition for health ingredients, with more than 500 global suppliers registered to attend. HiE promotes itself as the leading European venue to engage with business partners and solution providers in the $1 trillion health, natural and nutritional food and beverage industry.



The weight management yoghurt brings together the joint expertise of OptiBiotix Health and Nizo Food Research. OptiBiotix is responsible for the weight management formulation, created by world experts in satiation (the feeling of fullness), metabolism and how microbes harvest energy in the gut whilst Nizo's specialist expertise lies in the manufacture of dairy products and using taste and texture to improve satiation.



Stephen O'Hara, CEO of OptioBiotix Health plc commented: "We are delighted to be presenting our unique weight management product at this year's HiE exhibition and exploring partnership opportunities with the many global suppliers attending this exhibition."

nice chart.

Early morning RNS.
very positive says Mr O'Hara.